Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Life-Threatening Delayed Myocardial Ischemia, Ventricular Arrhythmias, and SCD After PFA of AF: An Extended Case Series.

JACC. Clinical electrophysiology·2026
Same author

[Position paper of the German Society of Cardiology-quality criteria for performing catheter ablation of atrial fibrillation: executive summary].

Herzschrittmachertherapie & Elektrophysiologie·2026
Same author

Left atrial appendage closure in patients with non-valvular atrial fibrillation and end stage chronic KIDNEY disease: Rationale and design of the prospective randomized LAA-KIDNEY trial.

American heart journal·2026
Same author

Ultrasound-guided vs conventional venous puncture for atrial fibrillation ablation: the ULYSSES trial.

European heart journal·2026
Same author

Retraction notice to "Cognitive effects of cell-derived and synthetically-derived Aβ oligomers" [Neurobiol. Aging 32 (2009) 1784-1794].

Neurobiology of aging·2026
Same author

Severe cardiomyopathy due to permanent junctional reciprocating tachycardia: recovery after catheter ablation?-a case report.

European heart journal. Case reports·2026
Same journal

Incoming US science academy chief vows to 'double down' on research.

Nature·2026
Same journal

Author Correction: Synthesis of enantioenriched atropisomers by biocatalytic deracemization.

Nature·2026
Same journal

Electrodeposited self-assembled molecules for perovskite photovoltaics.

Nature·2026
Same journal

Neutrino's nursery found: the 'Shadow Blaster'.

Nature·2026
Same journal

Dementia risk in middle-aged people linked to a blood protein.

Nature·2026
Same journal

Daily briefing: What's really happening with trust in science.

Nature·2026
関連記事をすべて見る

関連する実験動画

Updated: May 11, 2026

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

基板を標的とするガンマ分泌酵素調節器

Thomas L Kukar1, Thomas B Ladd, Maralyssa A Bann

  • 1Department of Neuroscience, Mayo Clinic, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, Florida 32224, USA. kukar.thomas@mayo.edu

Nature
|June 13, 2008
PubMed
まとめ
この要約は機械生成です。

小分子ガンマ分泌酵素調節器 (GSM) は,ガンマ分泌酵素複合体自体ではなく,アミロイド前駆タンパク質 (APP) とアミロイドベータを標的にします. この二重作用は,アルツハイマー病の治療にシネジスティックなアプローチを提供する可能性があります.

さらに関連する動画

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
11:57

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

関連する実験動画

Last Updated: May 11, 2026

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
11:57

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

科学分野:

  • 神経科学は神経科学である.
  • バイオケミストリー バイオケミストリー
  • 薬理学 薬理学とは

背景:

  • アルツハイマー病 (AD) の治療は,ガンマ分泌酵素調節剤 (GSM) を使用してアミロイドベータ42 (Abeta42) を低下させることを目標としています.
  • ガンマ分泌酵素経路内のGSMの正確な分子標的は,まだ完全に理解されていません.
  • GSM標的を特定することは,効果的なAD治療法の開発に不可欠です.

研究 の 目的:

  • 小分子ガンマ分泌酵素調節器 (GSMs) の直接的な分子標的を特定する.
  • GSMがアベタ42の生成とアミロイドベータの結合を調節するメカニズムを解明する.
  • アルツハイマー病に対する基板標的型GSMの治療の可能性を調査する.

主な方法:

  • バイオチニル化光活性化GSM (フォトプローブ) の開発と応用.
  • ヒトのニューログリオマH4細胞におけるアフィニティラベリングアッセイで,タンパク質標的を特定する.
  • 様々なGSMによる競争評価と,基板特有のラベリング実験.
  • アミロイド前駆タンパク質 (APP) の結合部位のサイト指向型変異.

主要な成果:

  • GSMのフォトプローバは,アミロイド前駆タンパク質 (APP),そのカルボキシ端末断片,およびアミロイドベータペプチドを標識したが,コアガンマ分泌酵素成分は標識しなかった.
  • GSMの相互作用は,アミロイドベータの残留体28-36に局限され,集積に重要な領域であった.
  • GSMは細胞由来アミロイドベータオリゴマーの産生を変化させ,APP変異はGSMの感受性に影響した.
  • GSMによる基板ラベル付けは,Notch.よりもAPPではより効率的でした.

結論:

  • GSMは,ガンマ分泌酵素複合体ではなく,APP基板を直接ターゲットにすることで作用します.
  • この基板標的化メカニズムは,アベタ42生成の調節とアミロイドベータ結合の抑制を結びつける.
  • この二重行動は,アルツハイマー病に対する潜在的にシネギスティックな治療戦略を提供し,薬剤の標的の概念を拡大します.